Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model

The Lancet

Volumn 393, Issue 10178, 2019, Pages 1319-1329

  Heffernan, Alastair ^a   Cooke, Graham S ^b   Nayagam, Shevanthi ^a,b   Thursz, Mark ^b   Hallett, Timothy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

CHINA; CHRONIC HEPATITIS C; DRUG EFFECT; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C; HUMAN; INCIDENCE; INDIA; MASS SCREENING; MORTALITY; ORGANIZATION AND MANAGEMENT; PAKISTAN; PREVALENCE; PROCEDURES; THEORETICAL MODEL; TRANSMISSION; WORLD HEALTH ORGANIZATION;

ANTIVIRAL AGENTS; CHINA; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INDIA; MASS SCREENING; MODELS, THEORETICAL; MORTALITY; PAKISTAN; PREVALENCE; WORLD HEALTH ORGANIZATION;

EID: 85063324322     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32277-3     Document Type: Article

References (71)

1. WHO. Global hepatitis report, 2017. 2017, World Health Organization, Geneva.
2. Westbrook, RH, Dusheiko, G, Natural history of hepatitis C. J Hepatol 61 (2014), s58–s68.
3. Thein, H-H, Yi, Q, Dore, GJ, Krahn, MD, Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008), 418–431.
4. Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease study 2013. Lancet 388 (2016), 1081–1088.
5. Alter, MJ, Epidemiology of hepatitis C virus infection. World J Gastroenterol, 13, 2007, 2436.
6. WHO. Global policy report on the prevention and control of viral hepatitis in WHO Member States. 2013, World Health Organization, Geneva.
7. Pépin, J, Abou Chakra, CN, Pépin, E, Nault, V, Valiquette, L, Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS One, 9, 2014, e99677.
8. Shepard, CW, Finelli, L, Alter, MJ, Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005), 558–567.
9. Wasley, A, Alter, MJ, Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000), 1–16.
10. Manns, MP, McHutchison, JG, Gordon, SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001), 958–965.
11. Yee, BE, Nguyen, NH, Zhang, B, et al. Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. BMJ Open Gastroenterol, 2, 2015, e000049.
12. Manns, MP, Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006), 1350–1359.
13. Afdhal, N, Reddy, KR, Nelson, DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370 (2014), 1483–1493.
14. Lawitz, E, Mangia, A, Wyles, D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
15. Forns, X, Lee, SS, Valdes, J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17 (2017), 1062–1068.
16. Lens, S, Fernández, I, Rodríguez-Tajes, S, et al. Interferon-free therapy in elderly patients with advanced liver disease. Am J Gastroenterol, 112, 2017, 1400.
17. WHO. Global health sector strategy on viral hepatitis 2016–2021. 2016, World Health Organization, Geneva.
18. Bedossa, P, Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994), 15–20.
19. United Nations Population Division. World Population Prospects. https://esa.un.org/unpd/wpp/, 2017. (Accessed 30 November 2017)
20. United Nations Office on Drugs and Crime. Booklet 2: global overview of drug demand and supply. World Drug Report 2017, 2017, United Nations, Vienna.
21. Mathers, BM, Degenhardt, L, Bucello, C, Lemon, J, Wiessing, L, Hickman, M, Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 91 (2013), 102–123.
22. Innes, HA, McDonald, SA, Dillon, JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
23. El-Kamary, SS, Jhaveri, R, Shardell, MD, All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 53 (2011), 150–157.
24. WHO. Monitoring and evaluation for viral hepatitis B and C: recommended indicators and framework. 2016, World Health Organization, Geneva.
25. Cacoub, P, Comarmond, C, Domont, F, Savey, L, Desbois, AC, Saadoun, D, Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3 (2016), 3–14.
26. Sherman, AC, Sherman, KE, Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 12 (2015), 353–361.
27. Razavi, H, Robbins, S, Zeuzem, S, et al. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 325–336.
28. WHO. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low-and middle-income countries. 2018, World Health Organization, Geneva.
29. Martin, NK, Vickerman, P, Grebely, J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
30. Chen, SL, Morgan, TR, The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3 (2006), 47–52.
31. Seeff, LB, Natural history of chronic hepatitis C. Hepatology 36 (2002), s35–s46.
32. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2 (2017), 161–176.
33. Degenhardt, L, Peacock, A, Colledge, S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health 5 (2017), e1192–e1207.
34. Institute for Health Metrics and Evaluation. GBD results tool. http://ghdx.healthdata.org/gbd-results-tool, 2017. (Accessed 13 October 2017)
35. Raftery, AE, Bao, L, Estimating and projecting trends in HIV/AIDS generalized epidemics using incremental mixture importance sampling. Biometrics 66 (2010), 1162–1173.
36. Platt, L, Minozzi, S, Reed, J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis: OST and NSP to prevent HCV transmission. Addiction 113 (2017), 545–563.
37. Hagan, H, Pouget, ER, Des Jarlais, DC, A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 204 (2011), 74–83.
38. WHO UNODC, UNAIDS. WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users—2012 revision. 2012, World Health Organization, Geneva.
39. Larney, S, Peacock, A, Leung, J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health 5 (2017), e1208–e1220.
40. Razavi, H, Waked, I, Sarrazin, C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 21:suppl 1 (2014), 34–59.
41. Chan, HLY, Chen, CJ, Omede, O, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm—volume 4. J Viral Hepat 24:suppl 2 (2017), 25–43.
42. Hatzakis, A, Chulanov, V, Gadano, AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm—volume 2. J Viral Hepat 22:suppl 1 (2015), 26–45.
43. Sibley, A, Han, KH, Abourached, A, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm—volume 3. J Viral Hepat 22:suppl 4 (2015), 21–41.
44. WHO. Global report on access to hepatitis C treatment. Focus on overcoming barriers. 2016, World Health Organization, Geneva.
45. UNAIDS. Fast track: ending the AIDS epidemic by 2030. 2014, Joint United Nations Programme on HIV/AIDS, Geneva.
46. Tucker, JD, Meyers, K, Best, J, et al. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. BMC Infect Dis, 17(suppl 1), 2017, 701.
47. Grebely, J, Lamoury, FM, Hajarizadeh, B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. Lancet Gastroenterol Hepatol 2 (2017), 514–520.
48. Grebely, J, Applegate, TL, Cunningham, P, Feld, JJ, Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert Rev Mol Diagn 17 (2017), 1109–1115.
49. Martin, NK, Vickerman, P, Dore, GJ, Hickman, M, The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS 10 (2015), 374–380.
50. Harris, M, Albers, E, Swan, T, The promise of treatment as prevention for hepatitis C: meeting the needs of people who inject drugs?. Int J Drug Policy 26 (2015), 963–969.
51. Strathdee, SA, Hallett, TB, Bobrova, N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 376 (2010), 268–284.
52. Wolfe, D, Carrieri, MP, Shepard, D, Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376 (2010), 355–366.
53. Palmateer, NE, Taylor, A, Goldberg, DJ, et al. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. PLoS One, 9, 2014, e104515.
54. Cook, C, Davies, C, The lost decade: neglect for harm reduction funding and the health crisis among people who use drugs. 2018, Harm Reduction International, London.
55. WHO. The 2016 global status report on blood safety and availability. 2017, World Health Organization, Geneva.
56. Hutin, Y, Hauri, A, Chiarello, L, et al. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bull World Health Organ 81 (2003), 491–500.
57. Qureshi, H, Bile, KM, Jooma, R, Alam, SE, Afridi, HUR, Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J, 16, 2010, S15.
58. Reeler, AV, Anthropological perspectives on injections: a review. Bull World Health Organ 78 (2000), 135–143.
59. Gore, C, Lazarus, JV, Peck, RJJ, Sperle, I, Safreed-Harmon, K, Unnecessary injecting of medicines is still a major public health challenge globally. Trop Med Int Health 18 (2013), 1157–1159.
60. UN Sustainable Development Knowledge Platform. Sustainable Development Goals. https://sustainabledevelopment.un.org/sdgs, 2018. (Accessed 9 August 2018)
61. Gountas, Sypsa, Anagnostou, O, et al. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: Is elimination possible in a high prevalence setting?. Addict Abingdon Engl 112 (2017), 1290–1299.
62. Fraser, H, Martin, NK, Brummer-Korvenkontio, H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 68 (2018), 402–411.
63. Lim, AG, Qureshi, H, Mahmood, H, et al. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol 47 (2018), 550–560.
64. US Centres for Disease Control and Prevention. Increase in hepatitis C infections linked to worsening opioid crisis. https://www.cdc.gov/nchhstp/newsroom/2017/hepatitis-c-and-opioid-injection.html, Feb 19, 2018. (Accessed 15 May 2018)
65. Roy, É, Arruda, N, Bruneau, J, Jutras-Aswad, D, Epidemiology of injection drug use: new trends and prominent issues. Can J Psychiatry 61 (2016), 136–144.
66. European Monitoring Centre for Drugs and Drug Addition. Trends in injecting drug use in Europe. 2010, Publications Office of the European Union, Luxembourg.
67. Information Services Division. Scottish drug misuse database: overview of initial assessments for specialist drug treatment 2016/17. 2018, NHS National Services Scotland, Edinburgh.
68. Hughes, CE, Stevens, A, What can we learn from the Portuguese decriminalization of illicit drugs?. Br J Criminol 50 (2010), 999–1022.
69. Heffernan, A, Barber, E, Cook, NA, et al. Aiming at the global elimination of viral hepatitis: challenges along the care continuum. Open Forum Infect Dis, 5, 2018, ofx252.
70. Alcorn, K, Australia shows an alternative to rationing hepatitis C treatment. NAM Aidsmap. http://www.aidsmap.com/page/3061523/, June 6, 2016. (Accessed 20 November 2016)
71. Wylie, L, Hutchinson, S, Liddell, D, Rowan, N, The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. BMC Infect Dis, 14(suppl 6), 2014, S7.